Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials

Sound Shore Management's Q2 2026 investor letter discusses Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and its mixed clinical trial results for its melanoma drug. The biotech company's stock closed at $814.79 per share in August 2026, with a market capitalization of $83.89 billion. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) saw a 10.35% return over the past month and a 40.58% gain over the past 52 weeks.

The investment firm initiated its position when the stock was trading at an attractive 13 times earnings with an 8% free cash flow yield. Despite the company's promising pipeline drugs, Sound Shore Management decided not to include Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its list of 40 Most Popular Stocks Among Hedge Funds, as it believes AI stocks offer greater upside potential and less downside risk.